TriSalus Life Sciences
TLSI
72 hedge funds and large institutions have $232M invested in TriSalus Life Sciences in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 14 increasing their positions, 12 reducing their positions, and 5 closing their positions.
17% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 12
0% more capital inflows, than outflows
Capital inflows: $27.1M | Capital outflows: $27.1M
0% more funds holding
Funds holding: 72 → 72 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
0.01% less ownership
Funds ownership: 93.66% → 93.64% (-0.01%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Capital Management
Chicago,
Illinois
|
+$6.38M |
| 2 |
Mizuho Securities USA
New York
|
+$4.53M |
| 3 |
AQR Arbitrage
Greenwich,
Connecticut
|
+$2.62M |
| 4 |
Jane Street
New York
|
+$2.02M |
| 5 |
Boothbay Fund Management
New York
|
+$1.88M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Kryger Capital
London,
United Kingdom
|
-$6.17M |
| 2 |
AC
Antara Capital
New York
|
-$4.92M |
| 3 |
Magnetar Financial
Evanston,
Illinois
|
-$4.06M |
| 4 |
Millennium Management
New York
|
-$3.52M |
| 5 |
Goldman Sachs
New York
|
-$3.02M |
TLSI Hedge Fund Activity: Q3 2022 in Review
72 of the 5,831 institutional investors tracked by Wall St. Rank reported a position in TriSalus Life Sciences (TLSI) for Q3 2022, worth a combined $232M — up 0.86% from $230M a quarter earlier.
Fund positioning in TLSI was balanced in Q3 2022: 5 funds opened new positions, 5 closed out, 14 added to existing stakes and 12 trimmed.
The largest buyer was First Trust Capital Management, adding an estimated $6.38M. The largest seller was Kryger Capital, cutting an estimated $6.17M.
- 72 institutional investors held TriSalus Life Sciences (TLSI) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $232M of TriSalus Life Sciences stock for Q3 2022, up 0.86% quarter-over-quarter.
- 5 funds opened new TriSalus Life Sciences positions in Q3 2022 and 5 closed out, a net change of 0 holders.
- The largest TriSalus Life Sciences buyer in Q3 2022 was First Trust Capital Management, an estimated $6.38M added.
- The largest TriSalus Life Sciences seller in Q3 2022 was Kryger Capital, an estimated $6.17M sold.
Based on aggregated 13F filings for Q3 2022.